ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 78 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,841,345 | -41.7% | 5,591,947 | -8.8% | 0.00% | -50.0% |
| Q2 2023 | $46,040,348 | -16.9% | 6,130,539 | -50.0% | 0.00% | +33.3% |
| Q1 2023 | $55,410,146 | -19.6% | 12,258,882 | +100.5% | 0.00% | -57.1% |
| Q4 2022 | $68,898,334 | +55.5% | 6,113,428 | +32.0% | 0.01% | +40.0% |
| Q3 2022 | $44,315,000 | +37.4% | 4,630,574 | +16.2% | 0.01% | +66.7% |
| Q2 2022 | $32,248,000 | -46.4% | 3,986,214 | +12.0% | 0.00% | -40.0% |
| Q1 2022 | $60,147,000 | +7.9% | 3,558,954 | +37.3% | 0.01% | +25.0% |
| Q4 2021 | $55,722,000 | -40.1% | 2,592,939 | +105.9% | 0.00% | -42.9% |
| Q3 2021 | $93,020,000 | +34.6% | 1,259,416 | -0.4% | 0.01% | +40.0% |
| Q2 2021 | $69,114,000 | -25.0% | 1,263,973 | +1.2% | 0.01% | -37.5% |
| Q1 2021 | $92,139,000 | +0.0% | 1,249,508 | +16.9% | 0.01% | 0.0% |
| Q4 2020 | $92,105,000 | +225.9% | 1,068,499 | +42.7% | 0.01% | +166.7% |
| Q3 2020 | $28,261,000 | – | 748,830 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |